glp-1 weight loss journey Loss: My 14-Week, 32-Pound Before & After Journey! My GLP-1 Weight Loss Journey:

The engineered drug localized to lipid-rich plaque regions and CD11b/CD11c inflammatory cells, effectively suppressing inflammatory responses and enhancing cholesterol efflux ( By promoting cholesterol efflux and reducing foam-cell content within plaques, GLP-1RA therapy may decrease lipid core size and necrotic burden, thereby stabilizing the fibrous cap, lowering the risk of plaque rupture, and potentially reducing acute coronary events

Not perfect

The DPP-4 inhibitor CV safety outcome trials have unequivocally demonstrated that DPP-4 inhibition is not associated with any increased risk of major adverse CV events (MACE), with the four trials so far published (124127) having hazard ratios (HR) for the primary outcome of between 0.96 and 1.02 (Table 2)

This approach represents a fundamental shift from the conventional more is better mentality in medicine